DigestRedComo funciona
Red
/
Empresas
Cr
No verificado

Crinetics Pharmaceuticals, Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaMedicina Salud Bienestar

4 Comunicados de prensa

Ver todos los comunicados de prensa
22/01/2026
Biotecnología
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Fuente
Crinetics Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0
11/12/2025
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Fuente
Crinetics Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0
03/12/2025
Biotecnología
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Fuente
Crinetics Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0
25/09/2025
Biotecnología
Medicina Salud Bienestar
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Fuente
Crinetics Pharmaceuticals, Inc.
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0